CD69 and glioblastoma: The present study provides first evidence that low Hsp70 levels and elevated proportions of activated CD94+/CD69+ NK cells able to recognize mHsp70+ tumor cells (Multhoff et al., 1999) in glioblastoma patients might favor a beneficial clinical outcome.